English | 简体中文 | 繁體中文 | 한국어 | 日本語
Saturday, 7 March 2020, 09:00 HKT/SGT

Source: Novotech
Novotech Wins CRO Contract for Komipharm Coronavirus Covid-19 Clinical Trial in South Korea

SEOUL, KOREA, Mar 7, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus - Covid-19. Komipharm is seeking to expand the use of Panaphix to cover the treatment of Covid-19 through this trial.

Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines. The overproduction of immune cells and their signalling molecules leads to severe inflammatory disease such as pneumonia in some individuals.

Novotech CEO Dr Moller said Novotech was well positioned to partner with Komipharm on this important trial of a drug which is having a particularly strong impact in Asia Pacific. Novotech has offices in eleven locations throughout Asia Pacific, with experienced local leadership, the ability to engage with regulators, strong relationships with key opinion leaders, and sites in the region will allow it to accelerate this trial.

Novotech undertakes a large number of infectious diseases trials and has particularly strong relationships in this area. Novotech recently won the Australian-Korean Business Awards 2020 - Award for Excellence, in the category Biotech and Health.

Over the last 12 months Novotech has signed several formal partnerships with key hospitals in Korea, including Seoul National University, Asan Medical Center, Yonsei University Severance Hospital, and Ulsan University Hospital, to facilitate the project management of clinical trials and accelerate biotech drug development.

About Novotech
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets.

Novotech also has worldwide reach through the company's network of strategic partners. https://novotech-cro.com/welcome. For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

Media Contact:
Susan Fitzpatrick-Napier
[email protected]
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Topic: Clinical Trial Results
Sectors: BioTech, HealthCare
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Novotech Releated News
June 1, 2020 09:00 HKT/SGT
Novotech 与 Endpoints News 合作举办有关亚太地区临床试验前景的系列网络研讨会
June 1, 2020 09:00 HKT/SGT
Novotech 與 Endpoints News 合作舉辦有關亞太地區臨床試驗前景的系列網絡研討會
May 28, 2020 11:00 HKT/SGT
노보텍 (Novotech)과 엔드포인츠 뉴스 (Endpoints News), 아시아 태평양 지역 임상시험 동향을 조망하는 웨비나 (Webinar) 시리즈를 위해 협력
May 26, 2020 19:00 HKT/SGT
Novotech and Endpoints to present APAC Clinical Trial webinar series
May 20, 2020 11:00 HKT/SGT
经申办方推选,Novotech 荣获“CRO 领导力大奖”
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575